HC Wainwright & Co. Reiterates Buy on Tenaya Therapeutics, Maintains $18 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Joseph Pantginis has reiterated a 'Buy' rating on Tenaya Therapeutics (NASDAQ:TNYA) and maintained an $18 price target.
August 10, 2023 | 11:37 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Tenaya Therapeutics' stock rating has been reiterated as 'Buy' by HC Wainwright & Co. with a maintained price target of $18.
The reiteration of a 'Buy' rating by a reputable analyst firm like HC Wainwright & Co. is a positive signal for investors. The maintained price target of $18 also indicates the firm's confidence in the stock's potential. This could lead to increased investor interest and potentially a short-term increase in the stock's price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100